证券日报网讯 2月27日，麦克奥迪在互动平台回答投资者提问时表示，作为国有控股上市公司，公司长 期以来致力于做好经营管理，提升公司内在价值，切实维护股东权益。自上市以来，公司已连续13年坚 持实施年度现金分红。公司坚持回报投资者，并努力实现国有资产的保值增值。公司将沿着既定方向， 持续提高经营质量，努力为股东创造更多价值。 （文章来源：证券日报） ...

证券日报网讯 2月13日，麦克奥迪在互动平台回答投资者提问时表示，二级市场股价受多种因素共同作 用影响，具有不确定性，敬请注意投资风险。公司将持续聚焦主业发展，提升经营质效，切实维护股东 权益。 （文章来源：证券日报） ...

Core Viewpoint - The company McAudie has initiated legal proceedings against Shenyang Sixth People's Hospital for unpaid dues totaling 320 million yuan, which includes a principal amount of 259 million yuan and overdue payment penalties of 28.26 million yuan, along with a request for contract termination and additional penalties of 33 million yuan [1] Group 1 - McAudie's subsidiary, Liaoning McAudie Medical Equipment Co., Ltd., has filed a lawsuit in Shenyang, with the case already accepted by the court [1] - The lawsuit stems from Shenyang Sixth People's Hospital's failure to make payments as per the procurement contract signed on October 14, 2022, which outlined the procurement and payment terms for medical consumables [1] - Since April 2024, Shenyang Sixth People's Hospital has not made any payments, prompting Liaoning McAudie to terminate the contract on September 15, 2025, after multiple unsuccessful payment reminders [1]

Policy Developments - The National Health Commission announced the initiation of HPV vaccination for eligible girls starting in late February, aiming to provide free vaccination services to prevent high-risk HPV infections and reduce cervical cancer incidence [2]. Drug and Device Approvals - Fosun Pharma's subsidiary received approval for clinical trials of HLX15-SC, a monoclonal antibody for multiple myeloma treatment, with a cumulative R&D investment of approximately RMB 191.53 million expected by January 2026 [4]. - Hanyu Pharmaceutical received FDA approval for its acetate glatiramer injection, which treats relapsing multiple sclerosis, enhancing its product pipeline in the U.S. market [5]. Capital Markets - Guangji Pharmaceutical plans to raise up to RMB 600 million through a private placement of shares to repay loans and supplement working capital, pending necessary approvals [7]. - Bonasia and Zhejiang Jingxin Pharmaceutical submitted applications for listing on the Hong Kong Stock Exchange, with respective sponsors [8][9]. Clinical Innovations - A successful brain-machine interface surgery was performed in Guangxi, marking a significant advancement in clinical applications of this technology, with the market projected to reach RMB 3.2 billion by 2024, growing at 18.8% [10]. Research Developments - Researchers from the Wuhan Institute of Virology reported that the oral nucleoside prodrug VV261 effectively inhibits Chikungunya virus replication, supporting its potential new indications [11]. - Northwestern University scientists developed an advanced human spinal cord injury organoid model, providing a platform for testing new regenerative therapies [12]. Public Sentiment Alerts - McAudie announced a lawsuit against Shenyang Sixth People's Hospital over a contract dispute involving over RMB 319.82 million, with the case currently accepted by the court [14]. - The National Medical Insurance Administration listed 153 companies as "discredited," which may face restrictions on their products and services based on their credit ratings [15].

Group 1 - The People's Bank of China announced a 1 trillion yuan reverse repurchase operation to maintain liquidity in the banking system, indicating a reduced urgency for a short-term reserve requirement ratio cut [1] - Analysts suggest that the large liquidity injection allows for observation of effects before implementing broader monetary tools like a reserve requirement ratio cut, which remains an important option in the central bank's toolkit [1] Group 2 - Shenzhen's Industrial and Information Technology Bureau released an action plan for "Artificial Intelligence + Advanced Manufacturing" aimed at enhancing the semiconductor industry through AI applications [2] - The plan focuses on optimizing chip design and software code efficiency, and developing high-performance AI chips to meet the demands of various AI terminals [2] Group 3 - The Ministry of Industry and Information Technology is soliciting public opinions on mandatory national standards for the safety requirements of autonomous driving systems in intelligent connected vehicles [6] Group 4 - The Shanghai Stock Exchange plans to reduce market operating costs, expecting to return approximately 1.113 billion yuan to the market in 2026 through various initiatives [8] - The initiatives include optimizing information disclosure channels and enhancing regulatory service quality [8] Group 5 - The Ministry of Commerce proposed to impose countervailing duties on imported dairy products from the European Union, effective February 13, 2026 [9] Group 6 - The National Development and Reform Commission aims to establish a mandatory insurance system for unmanned aerial vehicles by 2027, enhancing the safety framework for low-altitude economic activities [10] Group 7 - The film industry is being targeted for consumption growth through a "Film +" initiative, with expectations for significant box office performance during the upcoming Spring Festival holiday [12] - Analysts highlight potential investment opportunities in film content producers, leading cinema companies, and firms with strong film production and marketing capabilities [12] Group 8 - A list of undervalued media stocks with projected earnings growth of over 100% has been compiled, indicating potential investment opportunities in the film and media sector [13]

Group 1 - Fuda Alloy's controlling shareholder Wang Dawu plans to reduce his stake by up to 3% of the company's total shares, amounting to a maximum of 406.34 million shares, due to personal funding needs [1] - ST Songfa's subsidiary signed contracts for the construction of 17 vessels, with a total contract value between 1.6 billion to 1.8 billion USD [2] - Pairui Co. signed a technical cooperation agreement with a university to develop large-capacity power semiconductor devices and related power electronic modules, effective for three years [3] Group 2 - Shuangliang Energy indirectly participates in commercial aerospace projects, supplying heat exchangers for SpaceX's fuel production system, with orders totaling approximately 1.39 million CNY [4] - Hangya Technology plans to issue convertible bonds to raise up to 600 million CNY for various projects, including an intelligent manufacturing base in Malaysia [5] - Yuhua Development is publicly selling assets with a base price of 251 million CNY for residential properties [6] Group 3 - Penghui Energy plans to invest 2.1 billion CNY in a new battery production project in Zhengyang County, Henan Province, focusing on high-performance battery products [7] - Haige Communication's shareholder Yang Haizhou intends to reduce his stake by up to 0.1624% of the company's total shares [8] - Yaoshi Technology's controlling shareholder pledged 5.13% of shares to repay loans, with a pledge period from February 10, 2026, to February 2, 2027 [9][10] Group 4 - Hanyu Pharmaceutical received FDA approval for its drug Acetate Glatiramer Injection, used for treating relapsing multiple sclerosis [11] - Baiyao Tai's GoliMab Injection received EMA approval for various indications, including rheumatoid arthritis and ulcerative colitis [12] - Jiangxi Tungsten Equipment plans to issue A-shares to raise up to 1.882 billion CNY for acquisitions [13] Group 5 - Hesong New Materials expects to recognize asset impairment provisions between 23.6 million to 28.5 million CNY for 2025 [14] - ST Meichen's subsidiary is involved in two major lawsuits with a total amount of approximately 31.9 million CNY [15] - China Coal Energy reported a 7.3% year-on-year decline in coal sales for January 2026, with total sales of 20.05 million tons [16] Group 6 - Yida Co. plans to adjust its epoxy propylene derivative project, reducing the total investment from 845 million CNY to 642 million CNY [17] - Fosun Pharma's subsidiary received approval for a clinical trial of HLX15-SC for multiple myeloma treatment [18][19] - Yinfeng Communication's board members and executives have terminated their share reduction plan [20] Group 7 - Huazhong High-tech has waived its preferential purchase rights for a fund, extending the investment period from three to four years [21] - Warner Pharmaceuticals plans to participate in a national drug procurement program, with expected sales of 176 million CNY [22] - Changling Hydraulic announced a tender offer to acquire 12% of its shares at a price of 35.82 CNY per share [23] Group 8 - ST Chuan Zhi's stock may face delisting due to financial data falling below regulatory thresholds [24] - Tian Pharmaceutical and its subsidiaries are participating in a national drug procurement program, with expected sales of 323 million CNY [25] - China Metallurgical Group signed new contracts worth 73.65 billion CNY in January 2026 [26] Group 9 - Torus plans to invest 21.2 million CNY in a venture capital fund focused on artificial intelligence [27] - Shangwei Co. received a government subsidy of 1.764 million CNY, representing 10.79% of its net profit for 2024 [28] - Hanghua Co. reported a 21.97% decline in net profit for 2025, with total revenue of 1.249 billion CNY [29] Group 10 - Huaxia Bank reported a 1.72% decline in net profit for 2025, with total revenue of 91.914 billion CNY [30] - Guotou Fengle plans to transfer 51% of its stake in Hubei Fengle Ecological Fertilizer to optimize management [31] - Huaru Technology is co-investing in a fund with a total commitment of 20 million CNY [32] Group 11 - Jindike reported a loss of 173 million CNY for 2025, despite a 40.13% increase in revenue [33] - Zhenong Co. announced a 0.52% increase in shares held by a major shareholder [34] - Maike Audi plans to recognize asset impairment provisions of approximately 52.55 million CNY [35] Group 12 - Fuan Pharmaceutical's subsidiary is expected to be selected for a national drug procurement program, with projected sales of 680 million CNY [36] - Rundu Co. is participating in a national drug procurement program, with some products expected to be selected [37] - Changqing Co. has postponed its large-scale die-casting project to March 2027 due to customer requirements [38] Group 13 - Pan Asia Micro透 received a patent for a graphene-based automotive headlight defogging device [39] - Luan An Huan Neng reported a 17.1% increase in raw coal production for January 2026, totaling 5 million tons [40] - Guangji Pharmaceutical received a drug registration certificate for Mecobalamin Tablets [41] Group 14 - Ruifeng New Materials announced the resignation of its deputy general manager for personal reasons [42] - Zhiguang Electric's subsidiary signed a procurement contract for energy storage equipment worth 210.4 million CNY [43] - Youyan Powder Materials reported a 19.41% increase in net profit for 2025 [44] Group 15 - Jincheng reported a 22.2% increase in net profit for 2025, with total revenue of 253 million CNY [46]

格隆汇2月12日丨麦克奥迪(300341.SZ)公布，根据《企业会计准则》及公司会计政策的相关规定，公司 及下属子公司对2025年12月末需计提减值准备的资产进行全面清查，并对资产可收回金额进行评估分 析，对可能发生资产减值损失的相关资产计提减值准备，预计2025年全年计提各类资产减值准备金额合 计约为5255.05万元。 ...

证券代码：300341 证券简称：麦克奥迪 公告编号：2026-003 麦克奥迪（厦门）电气股份有限公司 关于2025年度拟计提资产减值准备的公告 公司及董事会全体成员保证公告内容的真实、准确和完整，对公 告的虚假记载、误导性陈述或者重大遗漏负连带责任。 根据《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作》《企业会计准则》及公司会计政策等相关规定，为客观、真实、准确地 反映麦克奥迪（厦门）电气股份有限公司（以下简称"公司"）2025 年度财务状 况和经营成果，基于谨慎性原则，公司对截至 2025 年 12 月 31 日合并报表范围 内所属资产进行减值测试，拟对存在减值迹象的资产计提减值准备，具体情况如 下： 一、本期拟计提资产减值准备情况 根据《企业会计准则》及公司会计政策的相关规定，公司及下属子公司对 2025 年 12 月末需计提减值准备的资产进行全面清查，并对资产可收回金额进行 评估分析，对可能发生资产减值损失的相关资产计提减值准备，预计 2025 年全 年计提各类资产减值准备金额合计约为 5,255.05 万元，具体明细如下： 资产减值准备明细表 单位：万元 | 项目 | ...

关于子公司提起诉讼的公告 证券代码：300341 证券简称：麦克奥迪 公告编号：2026-002 麦克奥迪（厦门）电气股份有限公司 公司及董事会全体成员保证公告内容的真实、准确和完整，对公 告的虚假记载、误导性陈述或者重大遗漏负连带责任。 重要内容提示： 1、案件所处的诉讼阶段：立案受理。 4、对上市公司损益产生的影响：由于本案尚未开庭，本次公告的诉讼对公 司本期利润或期后利润的可能影响尚不确定。 一、本次诉讼事项的基本情况 麦克奥迪（厦门）电气股份有限公司（以下简称"公司"）控股子公司辽宁 麦克奥迪医疗器械有限公司（以下简称"辽宁器械"或"原告"）就与沈阳市第 六人民医院（沈阳市三级专科公立医院，以下简称"沈阳六院"或"被告"）买 卖合同纠纷一案，向沈阳市和平区人民法院提起诉讼，已收到沈阳市和平区人民 法院《受理案件通知书》。为切实维护公司的合法权益，公司在提起诉讼的同时 已向法院申请了财产保全措施。 二、本次案件基本情况 1 2、上市公司所处的当事人地位：原告。 3、涉案的金额：合计人民币 319,823,418.4 元。 （一）诉讼各方当事人 原告：辽宁麦克奥迪医疗器械有限公司 被告：沈阳市第六人民医院 ...

证券日报网讯1月30日，麦克奥迪（300341）在互动平台回答投资者提问时表示，公司管理层高度重视 股东利益，未来公司将继续加强技术创新和数字化转型，推动产品结构优化，在技术升级、全球化协同 与政策响应中寻找平衡，以韧性经营应对市场不确定性，努力为股东创造更大价值。 ...